CooperVision MyDay MiSight Q1 FY26 Revenue and Ramp Insights

Financial Analysis on MyDay MiSight Quarterly Revenue Contribution and Ramp Schedule in EMEA, Japan, and APAC

1. Revenue Contribution and Growth of MiSight and MyDay MiSight

• MiSight overall grew 23% to $28 million in the quarter, reflecting strong momentum in the myopia control segment ¹.
• The company projects 20% to 25% revenue growth from MiSight again this fiscal year, fueled by the success in new launches ².
• MyDay MiSight, a newer innovation combining proven myopia control efficacy and the comfort of a premium silicone hydrogel, was launched in EMEA in January and Japan in February, with extremely positive early reception reported ¹.

2. Geographic Breakdown and Market Context

• EMEA:

  • MyDay MiSight was launched in multiple European countries starting January.
  • The region showed strengthening commercial momentum with a combination of branded sales growth and new contract wins.
  • EMEA growth is expected to improve compared to Q1 due to contract execution and product launches with MyDay MiSight as a key growth driver ³⁴⁵.
  • Company indicates visibility of improving sales and confidence about momentum in EMEA associated with MyDay MiSight ⁶⁵.

• Japan:

  • The Japan launch was of regular MiSight (not MyDay MiSight) due to the regulatory timeline, achieving approval after about three years ⁷².
  • Japan is a very significant market for myopia control, with about 77% of elementary school children estimated to be myopic, representing a substantial opportunity ¹².
  • Despite a slower-than-expected start and softness in legacy hydrogel products impacting Asia Pac results negatively this quarter, active product launch efforts and leadership changes aim to reverse this ⁸³⁵.
  • Early indications for MiSight Japan are very positive following launch in February, with high clinician activation rates driving early momentum ¹².
  • The softer Asia Pac performance that includes Japan is expected to persist into Q2 but is forecasted to return to growth starting Q3, driven largely by new product launches including MiSight ⁸⁴⁵.

• Asia Pacific (excluding Japan):

  • MyDay MiSight was also launched in Australia, New Zealand, and South Africa with positive reception ⁷².
  • The region overall saw a 4% decline for CooperVision, primarily due to Japan's softness and legacy hydrogel sales ⁸.
  • Strategic investments to restore growth include leadership upgrades, marketing increases, and a new regional distribution center to speed fulfillment ⁸.
  • APAC is expected to remain down in Q2 but to return to growth in Q3, buoyed by product rollouts like MyDay MiSight and private label contract execution ⁸⁴⁵.

3. Ramp Schedule

• Q1 FY26: Early launch phases in EMEA (starting January) and Japan (February) with initial clinician engagement and professional educational programs underway ¹.
• Q2 FY26: Transitional quarter with continued execution of private label and branded product contracts; challenges remain in Japan and Asia Pac legacy product sales still weigh on results. EMEA and Americas expected to show sequential growth ⁴⁵.
• Q3 & Q4 FY26: Expectation that the bulk of contract executions, product launches, and private label collaborations ramp meaningfully, especially in EMEA and APAC regions. Asia Pac (including Japan) expected to return to growth on the back of these efforts ⁴⁵.
• The company identifies Q3 and Q4 as when all contracts and launches "really start coming together" and anticipates a return to "more consistent solid revenue growth" typical of CooperVision ⁴.

4. Supporting Commercial Efforts

• Launches are heavily supported by professional engagement programs, including major conferences, regional launch events, KOL (Key Opinion Leader) education, and media campaigns reaching tens of thousands of eye care professionals, which is driving strong clinician activation ¹.
• Management continues heavy investment in sales and marketing to maximize uptake and penetration ⁹.

5. Summary Table

---

Conclusion

The MyDay MiSight growth is contributing meaningfully to CooperVision’s quarterly revenues, with an estimated 23% growth and ~$28 million impact for MiSight in Q1 FY26. The product’s rollout across EMEA started in January, Japan in February (using regular MiSight), and selected APAC countries is progressing with positive early market feedback, supported by significant professional engagement efforts.

The ramp schedule indicates a gradual build with Q1 as launch phase, Q2 showing modest improvement but facing legacy headwinds—especially in Japan—and a more pronounced revenue ramp expected in Q3 and Q4 as private label contracts and broader commercial execution fully materialize. The company is confident in maintaining a 20–25% growth trajectory for MiSight and MyDay MiSight products in the current fiscal year, driven by broadening regional availability and enhanced marketing/sales efforts.

This growth strategy and ramp should help CooperVision continue to gain market share and counterbalance soft spots such as legacy hydrogel product pressures in Japan and APAC.

---

References:
All data points and quotes are supported by excerpts from Cooper Companies Q1 FY26 earnings transcript ^{7861013211121314415516917181920}, specifically citations ⁸¹²⁴⁵.